Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101) was written by Kang, Yoon-Koo;Yook, Jeong Hwan;Chang, Heung-Moon;Ryu, Min-Hee;Yoo, Changhoon;Zang, Dae Young;Lee, Jae-Lyun;Kim, Tae Won;Yang, Dae Hyun;Jang, Se Jin;Park, Young Soo;Lee, Young Jack;Jung, Hwoon-Yong;Kim, Jin-Ho;Kim, Byung Sik. And the article was included in Cancer Chemotherapy and Pharmacology in 2014.Safety of 1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione This article mentions the following:
Purpose: To improve the efficacy of adjuvant chemotherapy with mitomycin-C and fluoropyrimidine (Mf) in gastric cancer, we designed a new regimen (iceMFP) and investigated in a phase III study. Methods: We randomly assigned 640 patients with resectable and macroscopically recognizable serosa-invading gastric cancer to Mf or iceMFP group during operation. The Mf consisted of i.v. mitomycin-C (20 mg/m2) at 3-6 wk after surgery and oral doxifluridine (460-600 mg/m2/day) starting 4 wk after the administration of mitomycin-C and continuing for 3 mo. The iceMFP consisted of intraoperative i.p. cisplatin (100 mg), i.v. mitomycin-C (15 mg/m2) on postoperative day 1, followed by oral doxifluridine for 12 mo, and six monthly i.v. cisplatin (60 mg/m2). The primary endpoint was 3-yr recurrence-free survival (RFS). Results: A total of 521 patients (258 in Mf, 263 in iceMFP) were eligible for anal. after excluding patients with stage I disease, distant metastasis, or R1 resection. With a median follow-up of 3.5 years, the iceMFP group had a higher RFS (hazard ratio [HR] 0.70; 95 % confidence interval [CI] 0.54-0.90; p = 0.006; 3-yr RFS 60 % vs. 50 %) and overall survival (HR 0.71; 95 % CI 0.53-0.95; p = 0.02; 3-yr overall survival, 71 vs. 60 %) compared with the Mf group. This was confirmed at extension anal. after a median 6.6 years of follow-up. Both regimens were well tolerated with no differences in surgical complications. Conclusion: The efficacy of adjuvant Mf was significantly improved by the addnl. therapeutic strategies of iceMFP. Considering neg. results of AMC0201, these suggest that early initiation of chemotherapy and/or i.p. cisplatin played a distinct role in the improved efficacy. In the experiment, the researchers used many compounds, for example, 1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione (cas: 3094-09-5Safety of 1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione).
1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione (cas: 3094-09-5) belongs to tetrahydrofuran derivatives. THF (Tetrahydrofuran) is water-miscible and has a low viscosity making it a highly versatile solvent used in a variety of industries. Commercial tetrahydrofuran contains substantial water that must be removed for sensitive operations, e.g. those involving organometallic compounds. Although tetrahydrofuran is traditionally dried by distillation from an aggressive desiccant, molecular sieves are superior.Safety of 1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoropyrimidine-2,4(1H,3H)-dione
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem